Neurology

In vitro and cell culture studies identified an analog of the antibiotic novobiocin that inhibits the AHA1-Hsp90 interaction and could help treat AD and other tauopathies. Chemical synthesis, in vitro binding assays and HEK cell-based tau fibril formation assays of novobiocin analogs yielded a compound that inhibited AHA1-Hsp90 binding and decreased accumulation of insoluble tau and tau fibril formation in compared with vehicle. Next steps could include testing the compound in mouse models of AD and other tauopathies...